Manuel Valladares‐Ayerbes

Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer

Manuel Valladares‐Ayerbes, Margarita Reboredo, Vanessa Medina-Villaamil et al. · Journal of Translational Medicine · 2012 · 153 citations · Full text

Medicine, Cancer Biology, Oncology +17

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Jaafar Bennouna, István Láng, Manuel Valladares‐Ayerbes et al. · Investigational New Drugs · 2010 · 139 citations · Full text

Medicine, Oncology, Pharmacology +9

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study

Sheela Rao, Naureen Starling, David Cunningham et al. · Annals of Oncology · 2010 · 115 citations · Full text

Medicine, Oncology, Pharmacology +11

Circulating miR-200c and miR-141 and outcomes in patients with breast cancer

Silvia Antolín, Lourdes Calvo, M. Blanco et al. · BMC Cancer · 2015 · 94 citations · Full text

Medicine, Molecular Medicine, Oncology +17

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

Alfredo Carrato, Albert Abad, Bartomeu Massutí et al. · European Journal of Cancer · 2017 · 88 citations · Full text

Medicine, Oncology, Pharmacotherapy +17